DE3752062T2 - Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln - Google Patents

Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln

Info

Publication number
DE3752062T2
DE3752062T2 DE3752062T DE3752062T DE3752062T2 DE 3752062 T2 DE3752062 T2 DE 3752062T2 DE 3752062 T DE3752062 T DE 3752062T DE 3752062 T DE3752062 T DE 3752062T DE 3752062 T2 DE3752062 T2 DE 3752062T2
Authority
DE
Germany
Prior art keywords
drugs
manufacture
heterocyclic derivatives
attentional
hydroxytryptamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3752062T
Other languages
English (en)
Other versions
DE3752062D1 (de
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630077A external-priority patent/GB8630077D0/en
Priority claimed from GB868630074A external-priority patent/GB8630074D0/en
Priority claimed from GB868630076A external-priority patent/GB8630076D0/en
Priority claimed from GB878707175A external-priority patent/GB8707175D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE3752062D1 publication Critical patent/DE3752062D1/de
Application granted granted Critical
Publication of DE3752062T2 publication Critical patent/DE3752062T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3752062T 1986-12-17 1987-12-16 Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln Expired - Lifetime DE3752062T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868630077A GB8630077D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630074A GB8630074D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630076A GB8630076D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878707175A GB8707175D0 (en) 1987-03-25 1987-03-25 Medicaments

Publications (2)

Publication Number Publication Date
DE3752062D1 DE3752062D1 (de) 1997-06-12
DE3752062T2 true DE3752062T2 (de) 1997-09-11

Family

ID=27449858

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3752062T Expired - Lifetime DE3752062T2 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
DE3751404T Expired - Lifetime DE3751404T2 (de) 1986-12-17 1987-12-16 Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3751404T Expired - Lifetime DE3751404T2 (de) 1986-12-17 1987-12-16 Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen.

Country Status (7)

Country Link
US (1) US4985437A (de)
EP (3) EP0279990B1 (de)
JP (1) JP2608079B2 (de)
AT (2) ATE124865T1 (de)
DE (2) DE3752062T2 (de)
ES (1) ES2074981T3 (de)
GR (1) GR3017369T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948803A (en) * 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
WO1990014347A1 (en) * 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Indole derivatives and medicine
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
US5342845A (en) * 1990-08-31 1994-08-30 Nippon Shinyaku Company Limited Indole derivatives and drugs
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
EP0492020A1 (de) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
IT1250629B (it) * 1991-07-04 1995-04-21 Boehringer Ingelheim Italia Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
JPH08507514A (ja) * 1993-03-08 1996-08-13 藤沢薬品工業株式会社 脳血管性疾患を治療または予防するための薬物
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
BR0212477A (pt) * 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
HUP0402289A2 (hu) 2001-10-02 2005-02-28 Pharmacia & Upjohn Company Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
AU2003217275A1 (en) * 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
BR0307735A (pt) * 2002-02-19 2005-01-25 Upjohn Co Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença
BR0307874A (pt) * 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
MXPA05004723A (es) * 2002-11-01 2005-12-05 Pharmacia & Upjohn Co Llc Compuestos que tienen ambas actividades del agonista alfa 7 nachr y el antagonista 5ht para el tratamiento de las enfermedades del snc.
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
DE3445377A1 (de) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
ATE86110T1 (de) * 1984-12-20 1993-03-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
CH667657A5 (de) * 1985-01-07 1988-10-31 Sandoz Ag Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE385517T1 (de) * 1985-03-14 1991-07-25 Beecham Group P.L.C., Brentford, Middlesex, Gb Arzneimittel zur behandlung von erbrechen.
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
EP0498466B1 (de) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Derivate von Indazole-3-carboxamide und -3-carboxylsäure
EP0247266B1 (de) * 1986-01-07 1993-03-10 Beecham Group Plc Indolderivate mit einer azabicyclischen Seitenkette, Verfahren zu ihrer Herstellung, Zwischenprodukte und pharmazeutische Zusammensetzungen
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3801659A1 (de) * 1988-01-21 1989-07-27 Boehringer Ingelheim Kg Tetrahydropyridin - derivate
CA1332151C (en) * 1988-01-28 1994-09-27 Roman Amrein Use of a benzamide to treat cognitive disorder
DE68912822T2 (de) * 1988-05-16 1994-06-09 Searle & Co 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen.
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
ES2098273T3 (es) * 1989-10-16 1997-05-01 Hem Pharma Corp Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica.
IE65997B1 (en) * 1990-05-11 1995-11-29 Sankyo Co Piperidyloxy- and quinuclidinyloxy- isoxazole derivatives their preparation and their therapeutic use

Also Published As

Publication number Publication date
ATE152623T1 (de) 1997-05-15
GR3017369T3 (en) 1995-12-31
ATE124865T1 (de) 1995-07-15
DE3751404T2 (de) 1995-12-21
EP0559297A1 (de) 1993-09-08
EP0279990B1 (de) 1995-07-12
JPS63277623A (ja) 1988-11-15
EP0559297B1 (de) 1997-05-07
JP2608079B2 (ja) 1997-05-07
EP0551963A2 (de) 1993-07-21
EP0551963A3 (en) 1993-09-01
US4985437A (en) 1991-01-15
EP0279990A2 (de) 1988-08-31
DE3751404D1 (de) 1995-08-17
DE3752062D1 (de) 1997-06-12
EP0279990A3 (en) 1990-11-28
ES2074981T3 (es) 1995-10-01

Similar Documents

Publication Publication Date Title
DE3752062T2 (de) Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
FI931370A (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
ES2065691T3 (es) Derivados de quinuclidina.
DE3788057T2 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE3650647T2 (de) Arzneimittel zur Behandlung von Anxietas
NO871861D0 (no) Fremgangsmaate for fremstilling av nye dopamin beta-hydroxylase inhibitorer.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE182467T1 (de) Verwendung von antagonisten oder partiellen agonisten am 5-ht 1a-rezeptor zur behandlung und prävention von kognitiven störungen
ATE95704T1 (de) Anwendung heterozyklischer derivate zur herstellung von arzneimitteln.
NO176097C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte cykloheksener
BG103089A (en) Indoline derivatives useful as 5-ht-2c-receptor antagonists
ATE123942T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE68918449T2 (de) Siliziumverbindungen zur behandlung von knochen.
ATE96667T1 (de) Verwendung von heterocyclischen verbindungen zur behandlung von depressionen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition